//www.igerbera.com/journals/jamainternalmedicine The Most Cited articles published by JAMA Internal Medicine en-us Sat, 29 Apr 2023 19:43:46 GMT Sat, 29 Apr 2023 19:43:46 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2763184 Wed, 01 Jul 2020 00:00:00 GMT This cohort study describes risk factors and clinical characteristics and outcomes in 201 patients with coronavirus disease 2019 (COVID-19) pneumonia who developed acute respiratory distress syndrome or died. 180 7 934 943 10.1001/jamainternmed.2020.0994 2763184 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2764404 Mon, 01 Jun 2020 00:00:00 GMT This Viewpoint emphasizes the importance of mitigating the mental health consequences of social distancing in the COVID-19 era. 180 6 817 818 10.1001/jamainternmed.2020.1562 2764404 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2768601 Thu, 01 Oct 2020 00:00:00 GMT This cohort study evaluates the independent risk factors associated with mortality of patients with COVID-19 requiring treatment in the intensive care unit in the Lombardy region of Italy. 180 10 1345 1355 10.1001/jamainternmed.2020.3539 2768601 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2766086 Sat, 01 Aug 2020 00:00:00 GMT This cohort study examines the characteristics of patients admitted to the hospital with COVID-19 who will need admission to an intensive care unit, mechanical ventilation, or will die, and develops a COVID-19 risk score to predict outcomes. 180 8 1081 1089 10.1001/jamainternmed.2020.2033 2766086 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2772187 Fri, 01 Jan 2021 00:00:00 GMT This randomized clinical trial examines the effects of tocilizumab vs usual care in patients hospitalized with COVID-19 and moderate-to-severe pneumonia. 181 1 32 40 10.1001/jamainternmed.2020.6820 2772187 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2768602 Sun, 01 Nov 2020 00:00:00 GMT This cohort study of adults with COVID-19 examines factors associated with death and interhospital variation in treatment and outcomes in the US. 180 11 1436 1447 10.1001/jamainternmed.2020.3596 2768602 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2772186 Fri, 01 Jan 2021 00:00:00 GMT This randomized clinical trial evaluates the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19. 181 1 24 31 10.1001/jamainternmed.2020.6615 2772186 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2765641 Tue, 01 Sep 2020 00:00:00 GMT This study delineates the transmission dynamics of coronavirus disease 2019 (COVID-19) and evaluates the transmission risk at different exposure window periods before and after symptom onset. 180 9 1156 1163 10.1001/jamainternmed.2020.2020 2765641 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2767939 Tue, 01 Sep 2020 00:00:00 GMT In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening pneumonia and acute respiratory distress syndrome (ARDS). The mortality rate from COVID-19 ARDS can approach 40% to 50%. Although the mechanisms of COVID-19–induced lung injury are still being elucidated, the term cytokine storm has become synonymous with its pathophysiology, both in scientific publications and the media. Absent convincing data of their effectiveness in COVID-19, drugs such as tocilizumab and sarilumab, which are monoclonal antibodies targeting interleukin (IL)-6 activity, are being used to treat patients; trials of these agents typically cite the cytokine storm as their rationale (NCT04306705, NCT04322773). A critical evaluation of the term cytokine storm and its relevance to COVID-19 is warranted. 180 9 1152 1154 10.1001/jamainternmed.2020.3313 2767939 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2768834 Tue, 01 Dec 2020 00:00:00 GMT 这个横断面研究估计prevalence of severe acute respiratory syndrome coronavirus 2 antibodies in convenience samples from 10 geographic sites in the United States. 180 12 1576 1586 10.1001/jamainternmed.2020.4130 2768834 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2771095 Sun, 01 Nov 2020 00:00:00 GMT This randomized clinical trial examines the effect of 16:8-hour time-restricted eating on weight loss and metabolic risk markers. 180 11 1491 1499 10.1001/jamainternmed.2020.4153 2771095 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2769235 Sun, 01 Nov 2020 00:00:00 GMT This cohort study quantitatively describes molecular viral shedding in asymptomatic and symptomatic patients with SARS-CoV-2 infection. 180 11 1447 1452 10.1001/jamainternmed.2020.3862 2769235 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2768777 Thu, 01 Oct 2020 00:00:00 GMT This cross-sectional study examines trends in emergency department visits and visits that led to hospitalizations during a 4-month period leading up to and during the COVID-19 outbreak in the US. 180 10 1328 1333 10.1001/jamainternmed.2020.3288 2768777 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2772185 Fri, 01 Jan 2021 00:00:00 GMT 这个队列研究评估死亡率在patients with COVID-19 admitted to intensive care who were treated with tocilizumab. 181 1 41 51 10.1001/jamainternmed.2020.6252 2772185 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2768772 Thu, 01 Oct 2020 00:00:00 GMT This cross-sectional study uses 2018 data from the National Health and Aging Trends Study to assess the prevalence among older adults in the United States of unreadiness to access video or telephone telemedicine because of disability or inexperience with technology. 180 10 1389 1391 10.1001/jamainternmed.2020.2671 2768772 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2767980 Thu, 01 Oct 2020 00:00:00 GMT This observational study uses NCHS data to evaluate weekly changes in US deaths due to any cause and deaths due to pneumonia, influenza, or COVID-19, by state, from March 1 through May 30, 2020. 180 10 1336 1344 10.1001/jamainternmed.2020.3391 2767980 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2773059 Mon, 01 Mar 2021 00:00:00 GMT This cohort study examines trends in the use of telemedicine and in-person outpatient visits in 2020 among a national sample of 16.7 million individuals with commercial or Medicare Advantage insurance. 181 3 388 391 10.1001/jamainternmed.2020.5928 2773059 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2770172 Tue, 01 Dec 2020 00:00:00 GMT This cohort study examines the potential for airborne spread of COVID-19 through investigation of an outbreak among bus riders in Eastern China. 180 12 1665 1671 10.1001/jamainternmed.2020.5225 2770172 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2785004 Wed, 01 Dec 2021 00:00:00 GMT This randomized clinical trial evaluates the effects of therapeutic-dose low-molecular-weight heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. 181 12 1612 1620 10.1001/jamainternmed.2021.6203 2785004 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2764369 Wed, 01 Jul 2020 00:00:00 GMT This Viewpoint explores challenges in the Italian health care system during the coronavirus disease 2019 pandemic and how other countries can plan for optimal actions. 180 7 927 928 10.1001/jamainternmed.2020.1447 2764369 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2775397 Mon, 01 Mar 2021 00:00:00 GMT This systematic review and meta-analysis assesses the diagnostic accuracy of saliva nucleic acid amplification tests for diagnosis of coronavirus disease 2019. 181 3 353 360 10.1001/jamainternmed.2020.8876 2775397 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2773576 Thu, 01 Apr 2021 00:00:00 GMT This cross-sectional study examines the prevalence of persons with SARS-CoV-2 antibodies across the US and changes from July to September 2020. 181 4 450 460 10.1001/jamainternmed.2020.7976 2773576 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2768771 Thu, 01 Oct 2020 00:00:00 GMT This cross-sectional study uses data from the 2018 American Community Survey to assess disparities in digital access among Medicare beneficiaries by demographic and socioeconomic characteristics. 180 10 1386 1389 10.1001/jamainternmed.2020.2666 2768771 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2764748 Mon, 01 Jun 2020 00:00:00 GMT This Viewpoint stresses the importance of recognizing and directly addressing the challenges created by COVID-19 era physical distancing in the care of older adults. 180 6 819 820 10.1001/jamainternmed.2020.1661 2764748 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2774572 Thu, 01 Apr 2021 00:00:00 GMT This cohort study examines variations in COVID-19 mortality rates and over the first 6 months of the pandemic. 181 4 471 478 10.1001/jamainternmed.2020.8193 2774572 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2769741 Thu, 01 Oct 2020 00:00:00 GMT This cohort study examines the levels of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 in patients who recovered from mild coronavirus disease 2019. 180 10 1356 1362 10.1001/jamainternmed.2020.4616 2769741 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2776810 Sat, 01 May 2021 00:00:00 GMT This cohort study evaluates evidence of SARS-CoV-2 infection based on diagnostic nucleic acid amplification test among patients who tested positive versus negative for antibodies. 181 5 672 679 10.1001/jamainternmed.2021.0366 2776810 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2770542 Mon, 01 Mar 2021 00:00:00 GMT This case series examines the clinical outcomes for young adults hospitalized with COVID-19. 181 3 379 381 10.1001/jamainternmed.2020.5313 2770542 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2767106 Sat, 01 Aug 2020 00:00:00 GMT This cohort study examines the associations of dietary scores for 4 healthy eating patterns with risk of incident cardiovascular disease. 180 8 1090 1100 10.1001/jamainternmed.2020.2176 2767106 //www.igerbera.com/journals/jamainternalmedicine/fullarticle/2771265 Mon, 01 Feb 2021 00:00:00 GMT This randomized clinical trial evaluates the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in health care workers with exposure to patients with COVID-19 at 2 hospitals in Philadelphia, Pennsylvania. 181 2 195 202 10.1001/jamainternmed.2020.6319 2771265

map